Abstract
Breast cancer, like other common cancers, tends to cluster in families, with disease being approximately twofold more common in first-degree relatives of cases [1–3]. The higher rate of most cancers in the monozygotic twins of cases than in dizygotic twins or siblings suggests that most of the familial clustering is the result of genetic variation rather than lifestyle or environmental factors [4,5]. Furthermore, simulation studies have shown that even if an environmental factor is perfectly correlated among relatives, it needs to confer at least a 10-fold increase in risk to result in even modest increases in familial relative risk
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Pharoah PDP, Day NE, Duffy S, Easton DF, Ponder BAJ. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 1997; 71:800–9.
Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001; 358:1389–99.
Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, et al. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med 2004; 1:e65.
Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark and Finland. N Engl J Med 2000; 343:78–85.
Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 2000; 26:411–4.
Hopper JL, Carlin JB. Familial aggregation of a disease consequent upon correlation between relatives in a risk factor measured on a continuous scale. Am J Epidemiol 1992; 136:1138–47.
Easton DF. How many more breast cancer predisposition genes are there? Breast Cancer Res 1999; 1:14–7.
Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62:676–89.
Smith P, McGuffog L, Easton DF, et al. A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer 2006; 45:646–55.
Antoniou AC, Pharoah PDP, McMullen G, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002; 86:76–83.
Wang WY, Barratt BJ, Clayton DG, Todd JA. Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet 2005; 6:109–18.
Pharoah PDP, Dunning AM, Ponder BAJ, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 2004; 4:850–60.
Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999; 286:2528–31.
Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31:55–9.
Vahteristo P, Bartkova J, Eerola H, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002; 71:432–8.
CHEK2 Breast Cancer Case–Control Consortium, Pharoah PDP. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from nine studies. Am J Hum Genet 2004; 74:1175–82.
Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006; 38:873–5.
Seal S, Thompson D, Renwick A, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006; 38:1239–41.
Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007; 39:165–7.
MacPherson G, Healey CS, Teare MD, et al. Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst 2004; 96:1866–9.
Frank B, Bermejo JL, Hemminki K, et al. Re: association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst 2005; 97:1012; author reply 1012–3.
Cox A, Dunning AM, Garcia-Closas M, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007; 39:352–8.
Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447:1087–93.
Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007.
Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2007; 39:865–9.
Garcia-Closas M, Hall P, Nevanlinna H, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008; 4e1000054.
Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407:770–6.
Adnane J, Gaudray P, Dionne CA, et al. BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene 1991; 6:659–63.
Moffa AB, Tannheimer SL, Ethier SP. Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Mol Cancer Res 2004; 2:643–52.
Jang JH, Shin KH, Park JG. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 2001; 61:3541–3.
Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446:153–8.
Smid M, Wang Y, Klijn JG, et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol 2006; 24:2261–7.
Pharoah PDP, Antoniou A, Bobrow M, Zimmern RL, Ponder BAJ, Easton DF. Polygenic susceptibility to breast cancer: implications for prevention. Nature Genet 2002; 31:33–6.
Antoniou AC, Easton DF. Polygenic inheritance of breast cancer: Implications for design of association studies. Genet Epidemiol 2003; 25:190–202.
Vineis P, Schulte P, McMichael AJ. Misconceptions about the use of genetic tests in populations. Lancet 2001; 357:709–12.
Antoniou AC, Durocher F, Smith P, Simard J, Easton DF. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res 2006; 8:R3.
Pharoah PDP, Mackay J. Absolute risk of breast cancer in women at increased risk: a more useful clinical measure than relative risk? The Breast 1998; 7:255–9.
Ioannidis JP. Why most published research findings are false? PLoS Med 2005; 2:e124.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Pharoah, P. (2009). High-Frequency Low-Penetrance Alleles. In: Welcsh, P. (eds) The Role of Genetics in Breast and Reproductive Cancers. Cancer Genetics. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0477-5_11
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0477-5_11
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0476-8
Online ISBN: 978-1-4419-0477-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)